Minireviews
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 24, 2019; 10(2): 38-51
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.38
Oligometastases in prostate cancer: Ablative treatment
Amalia Palacios-Eito, Amelia Béjar-Luque, Milagrosa Rodríguez-Liñán, Sonia García-Cabezas
Amalia Palacios-Eito, Amelia Béjar-Luque, Milagrosa Rodríguez-Liñán, Sonia García-Cabezas, Department of Radiation Oncology, Reina Sofia University Hospital, Cordoba 14004, Spain
Author contributions: All authors contributed to this manuscript.
Conflict-of-interest statement: The authors have no conflict of interest related to the manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Sonia García-Cabezas, MD, PhD, Associate Professor, Department of Radiation Oncology, Reina Sofia University Hospital, Avda. Menéndez Pidal, s/n, Cordoba 14004, Spain. songar1@gmail.com
Telephone: +34-95-7011415 Fax: +34-95-7011414
Received: August 24, 2018
Peer-review started: August 24, 2018
First decision: October 16, 2018
Revised: October 30, 2018
Accepted: January 9, 2019
Article in press: January 10, 2019
Published online: February 24, 2019
Processing time: 182 Days and 7.7 Hours
Abstract

Technological advances in radiotherapy have led to the introduction of techniques such as stereotactic body radiation therapy (SBRT), allowing the administration of ablative doses. The hypothesis that oligometastatic disease may be cured through local eradication therapies has led to the increasing use of SBRT in patients with this type of disease. At the same time, scientific advances are being made to allow the confirmation of clinically suspected oligometastatic status at molecular level. There is growing interest in identifying patients with oligometastatic prostate cancer (PCa) who may benefit from curative intent metastasis-directed therapy, including SBRT. The aim is to complement, replace or delay the introduction of hormone therapy or other systemic therapies. The present review aims to compile the evidence from the main ongoing studies and results on SBRT in relation to oligometastatic PCa; examine aspects where gaps in knowledge or a lack of consensus persist (e.g., optimum schemes, response assessment, identification and diagnosis of oligometastatic patients); and document the lack of first-level evidence supporting the use of such techniques.

Keywords: Oligometastases; Metastasis-directed therapy; Stereotactic body radiation therapy; Stereotactic ablative radiotherapy; Prostate cancer

Core tip: The hypothesis that oligometastatic disease may be cured with local eradication therapies has led to the growing use in prostate cancer (PCa) of treatments targeted to metastasis, including stereotactic body radiation therapy (SBRT). Such therapy intends to complement, replace or delay the introduction of systemic therapy. The present review aims to compile the evidence from the main ongoing studies and results on SBRT in relation to oligometastatic PCa, and examines aspects where gaps in knowledge persist, e.g., optimum schemes, response assessment, and identification and diagnosis of oligometastatic patients.